Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


RotaTeq recommended

Executive Summary

Merck's rotavirus vaccine RotaTeq was recommended for use by the Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices Feb. 21. The committee voted 12-0 with two abstentions for routine immunization of infants with three doses of the oral vaccine to be administered at two, four and six months of age. CDC analysis found that RotaTeq was not cost effective at the published price of $62 per dose, but could be cost effective at $42 per dose. RotaTeq was approved in early February (1"The Pink Sheet" Feb. 12, 2006, p. 25)...

You may also be interested in...

Merck RotaTeq Approval Will Bring Spring Shower Of Disease Awareness Ads

Merck will begin a targeted disease awareness print and internet advertising campaign this spring as part of the launch of the rotavirus vaccine RotaTeq

QUOTED. 15 April 2021. Philip Remedios.

As wearable medical devices become increasingly common for more complex applications, developers are facing questions about the industry’s direction and how they will protect consumers. See what Philip Remedios, director of design and development at Black Hagen Design said about it here. 

Rejecting FDA Advice, ACIP Defers J&J COVID Vaccine Blood Clot Decision Until It Gets More Data

US FDA suggested potential risk could be managed though a change in the fact sheet, but CDC committee wants more data, which could come within a week or so, to get a better sense of the frequency of the adverse events.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts